| Bioactivity | Casirivimab (REGN10933) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), it reduces viral load and improves diseases[1]. |
| Target | SARS-CoV-2 |
| Name | Casirivimab |
| CAS | 2415933-42-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. |